| # | Title | Journal | Year | Citations |
|---|
| 1 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | New England Journal of Medicine | 2015 | 6,773 |
| 2 | Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | New England Journal of Medicine | 2012 | 6,769 |
| 3 | Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer | New England Journal of Medicine | 2006 | 5,356 |
| 4 | Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer | New England Journal of Medicine | 2004 | 4,721 |
| 5 | Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer | New England Journal of Medicine | 2005 | 4,601 |
| 6 | Nonrigid registration using free-form deformations: application to breast MR images | IEEE Transactions on Medical Imaging | 1999 | 4,317 |
| 7 | Abiraterone and Increased Survival in Metastatic Prostate Cancer | New England Journal of Medicine | 2011 | 3,736 |
| 8 | Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial | Lancet, The | 2000 | 3,031 |
| 9 | Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Lancet, The | 2010 | 2,857 |
| 10 | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial | Lancet Oncology, The | 2015 | 2,353 |
| 11 | Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial | Lancet, The | 2006 | 2,349 |
| 12 | International uniform response criteria for multiple myeloma | Leukemia | 2006 | 2,332 |
| 13 | Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study | Lancet, The | 2017 | 2,267 |
| 14 | Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer | Clinical Cancer Research | 2008 | 1,975 |
| 15 | Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Lancet Oncology, The | 2014 | 1,932 |
| 16 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Lancet, The | 2014 | 1,833 |
| 17 | Diffusion-Weighted MRI in the Body: Applications and Challenges in Oncology | American Journal of Roentgenology | 2007 | 1,730 |
| 18 | Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial | Lancet, The | 2011 | 1,663 |
| 19 | Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2018 | 1,571 |
| 20 | Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial | Lancet, The | 2004 | 1,561 |
| 21 | Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group | Journal of the National Cancer Institute | 2011 | 1,505 |
| 22 | Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial | Lancet, The | 2017 | 1,475 |
| 23 | Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials | Lancet Oncology, The | 2015 | 1,369 |
| 24 | 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial | Lancet, The | 2007 | 1,361 |
| 25 | Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2016 | 1,351 |
| 26 | Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial | Lancet Oncology, The | 2016 | 1,344 |
| 27 | Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial | Lancet, The | 2014 | 1,295 |
| 28 | Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study | Lancet, The | 2001 | 1,249 |
| 29 | Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2016 | 1,212 |
| 30 | Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer | New England Journal of Medicine | 2016 | 1,205 |
| 31 | Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer | Lancet, The | 1998 | 1,195 |
| 32 | Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial | Lancet, The | 2015 | 1,175 |
| 33 | A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse | British Journal of Cancer | 2000 | 1,154 |
| 34 | Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing | Nature Genetics | 2014 | 1,103 |
| 35 | Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study | Lancet Oncology, The | 2015 | 1,100 |
| 36 | Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial | Lancet Oncology, The | 2016 | 1,091 |
| 37 | Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2014 | 1,039 |
| 38 | A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer | Nature Medicine | 2000 | 1,037 |
| 39 | Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) | Lancet, The | 2017 | 1,032 |
| 40 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms | Leukemia | 2022 | 1,023 |
| 41 | Body Mass Index, Serum Sex Hormones, and Breast Cancer Risk in Postmenopausal Women | Journal of the National Cancer Institute | 2003 | 963 |
| 42 | Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer | Journal of Clinical Oncology | 2009 | 948 |
| 43 | The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): Update 2011 on non-hepatic applications | Ultraschall in Der Medizin | 2012 | 922 |
| 44 | Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial | Lancet, The | 2018 | 901 |
| 45 | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma | Nature Medicine | 2018 | 900 |
| 46 | Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study | Lancet Oncology, The | 2014 | 890 |
| 47 | Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer | Science Translational Medicine | 2015 | 889 |
| 48 | Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial | Lancet Oncology, The | 2014 | 864 |
| 49 | ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma | International Journal of Gynecological Cancer | 2021 | 859 |
| 50 | Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry | Annals of Oncology | 2019 | 842 |
